AKT1 and non-small cell lung carcinoma: Furthermore, our data suggest that the effect of this novel combination may be limited by a prosurvival autophagy response, and that combining chloroquine with EGFR and AKT inhibition in the EGFR M+ NSCLC patient subgroup may be of additional benefit.